

# Combined ventilation and perfusion imaging using dynamic susceptibility contrast $^{19}\text{F}$ -MRI of inhaled perfluoropropane


Ben Pippard, Mary Neal, A John Simpson, Pete Thelwall

*Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne*


**Introduction:**  $^{19}\text{F}$ -MRI of inhaled perfluoropropane (PFP) is emerging as a viable approach to ventilation imaging in humans. However, the technique remains challenging owing to a short *in vivo*  $T_2^*$  ( $\sim 2\text{ms}^{-1}$ ) arising from magnetic susceptibility differences at gas-tissue interfaces. Previous pre-clinical studies have reported the ability to alter the magnetic susceptibility of lung tissue to match that of the airspaces, using intravenous paramagnetic contrast agents.<sup>2,3</sup> To date, no studies have assessed this susceptibility-matching effect in humans. We hypothesised that intravenous administration of a widely-used MR contrast agent (Gadobutrol) would lead to lengthened PFP  $T_2^*$  by reducing magnetic susceptibility differences between lung tissue and gas components in well perfused and well ventilated regions of the lung.

**Methods:** 6 healthy volunteers provided written informed consent and were screened for study eligibility. Participants were instructed to inhale a 79% PFP / 21% oxygen gas mixture on up to three occasions during a single MRI scan session. Each inhalation session comprised three deep breaths of gas followed by a breath-hold. During one gas inhalation, an intravenous dose of Gadobutrol (0.2mmol/kg) was administered via a MEDRAD power injector (up to 5ml/s), concurrent with the start of breath-hold. Dynamic unlocalised  $^{19}\text{F}$  pulse-acquire FID was performed in two participants. In the remaining participants, a dynamic 2D SPGR was initiated at the start of breath-hold. All imaging was performed on a Philips Achieva 3T scanner using a 20cm diameter  $^{19}\text{F}$  surface coil (PulseTeq Ltd., UK).

**Results:** Dynamic unlocalised spectroscopy demonstrated a transient rise in PFP  $T_2^*$  during passage of Gadobutrol through the lungs (Figure 1). Dynamic 2D  $^{19}\text{F}$ -MRI scans showed a corresponding increase in PFP signal intensity ( $\sim 20\%$ ) shortly after contrast administration (Figure 2). All scans were well tolerated with no adverse events.



**Figure 1:** Change in PFP  $T_2^*$  following Gadobutrol administration, showing a peak of 1.67ms at  $\sim 9$  s after injection of contrast (arrow).



**Figure 2:** Change in PFP signal intensity during a 2D  $^{19}\text{F}$ -MRI acquisition, showing  $\sim 20\%$  increase at 9 s after contrast administration.

**Conclusions:** We have demonstrated the ability to lengthen the  $T_2^*$  of inhaled PFP by concurrent administration of a paramagnetic contrast agent, reflecting transient susceptibility-matching at the gas tissue interface. To our knowledge, this is the first *in man* demonstration of this concept. The potential to assess lung microvascular perfusion properties through observed changes in PFP signal intensity offers a novel approach to combined ventilation/perfusion assessment, with implications for assessing gas exchange in a variety of respiratory pathologies.

**References:** 1. Couch MJ, *et al. Radiology* 2013;**269**:903-909. 2. Vignaud A, *et al. Magn Reson Med* 2005;**54**:28-33. 3. Dimitrov IE, *et al. J Magn Reson Imaging* 2005;**21**:149-155.